← Back to Search

Stem Cell Therapy

Approximately 100 million cells allogeneic hMSC for Alzheimer's Disease

Phase 1

Waitlist Available

Led By Bernard (Barry) Baumel, MD

Research Sponsored by Bernard (Barry) Baumel

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up one month post-infusion

Awards & highlights

Study Summary

This trial is testing whether mesenchymal stem cells are safe and effective for Alzheimer's disease.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ one month post-infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~one month post-infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and one month post-infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Incidence of any Treatment-Emergent Serious Adverse Events (TE-SAEs)

Secondary outcome measures

Biomarker levels over time

Apolipoprotein E

CSF PRA level over time

+13 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: hMSC Treatment groupExperimental Treatment1 Intervention

Participants in the hMSC treatment group will receive a total of 4 doses of the hMSC intervention. Each dose will be administered once about every 13 weeks within a year period.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Approximately 100 million cells allogeneic hMSC

2019

Completed Phase 1

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bernard (Barry) BaumelLead Sponsor

Bernard (Barry) Baumel, MD4.04 ReviewsPrincipal Investigator - University of Miami

University of Miami

3Patient Review

Our interactions began well, but as time went on he became quite arrogant. He talked over me and dismissed my concerns. His medical assistant followed suit. I'm now considering finding a new neurologist.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there any potential danger to patients from the utilization of approximately 100 million cells allogeneic hMSC?

"Given the Phase 1 status of this trial, which implies limited clinical data concerning safety and efficacy, Approximately 100 million cells allogeneic hMSC is estimated to have a score of 1 for safety."

Answered by AI

Am I able to register as a participant in this clinical experiment?

"This clinical trial searches for 6 individuals with alzheimer's between the ages of 50 and 85 who have consented to participate in writing. They should score a 20-26 on the Mini Mental State Examination, be positive for amyloid via PET scan or cerebrospinal fluid Aß1-42, have been taking cholinesterase inhibitors like donepezil, rivastigmine (oral or transdermal) or galantamine at a stable dose for 3 months prior to enrollment (optional), and meet criteria set by the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer"

Answered by AI

Does the study have an age restriction, and if so, what is the cut-off?

"Patients who wish to participate in this trial must be between the ages of 50 and 85."

Answered by AI

Is this clinical trial currently seeking participants?

"The specifics of this clinical trial, which was initially posted on October 8th 2019 and recently updated on August 15th 2022, indicate that it is not currently searching for participants. However, there are a multitude of other clinical trials actively recruiting patients at the moment - 546 in total."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Alzheimer's Disease Stem Cells Multiple Infusions

Bernard (Barry) Baumel 2019. "Alzheimer's Disease Stem Cells Multiple Infusions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04040348.